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Abstract 
There is a growing body of evidence that links epigenetic modifications to type 2 diabetes. 
Researchers have more recently investigated effects of commonly used medications, 
including those prescribed for diabetes, on epigenetic processes. This work reviews the 
influence of the widely used antidiabetic drug metformin on epigenomics, microRNA levels 
and subsequent gene expression and potential clinical implications. Metformin may influence 
the activity of numerous epigenetic modifying enzymes, mostly via modulating the activation 
of AMP-activated protein kinase (AMPK). Activated AMPK can phosphorylate numerous 
substrates, including epigenetic enzymes such as histone acetyltransferases (HATs), class II 
histone deacetylases (HDACs) and DNA methyltransferases (DNMTs), generally resulting in 
their inhibition, although HAT1 activity may be increased. Metformin has also been reported 
to decrease expression of multiple histone methyltransferases, increase the activity of the 
class III HDAC SIRT1 and to decrease the influence of DNMT inhibitors. There is evidence 
that these alterations influence the epigenome and gene expression, and may contribute to the 
antidiabetic properties of metformin and potentially protect against cancer, cardiovascular 
disease, cognitive decline and aging. The expression levels of numerous microRNAs are also 
reportedly influenced by metformin treatment and may confer antidiabetic and anticancer 
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activities. However, as the reported effects of metformin on epigenetic enzymes act to both 
increase and decrease histone acetylation, histone and DNA methylation, and gene 
expression, a significant degree of uncertainty exists on the overall effect of metformin on the 
epigenome, gene expression and subsequent effect on the health of metformin users. 
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Introduction 
Epigenetics is a rapidly growing field in medical research. Epigenetic modifications, changes to DNA 
structure that alter gene expression without altering the base nucleotide code, are crucial in the 
development of organisms and the differentiation and function of specific cell types. For example, 
epigenetic modifications permit the expression of the insulin gene in pancreatic β cells, while 
silencing it in other cells.1 However, epigenetic changes have also been associated with numerous 
disorders, including type 2 diabetes (T2D), CVD and cancer.2,3 Epigenetic processes can be altered by 
environmental factors including diet, exercise and exposure to toxins, with the foetal environment 
playing a particularly important role in influencing epigenetic modifications that impact metabolism 
in adult life; both maternal nutrient deficiency and maternal obesity have been linked to epigenetic 
changes and the development of T2D in offspring.4 There is growing evidence that pharmaceuticals 
also alter epigenetic processes, which may contribute to the beneficial and deleterious effects of 
widely-used medications.5 
As a result of the morbidities and growing prevalence of T2D, the use of medications designed to 
lower blood glucose is widespread and growing. The biguanide drug metformin is the most widely 
prescribed antidiabetic drug and is considered the gold standard for the treatment of T2D.6 In 2012, 
over 60 million prescriptions were filled for metformin in the United States, an increase of 97% from 
2003.7 Therefore, any epigenetic effects of metformin may affect the health of a significant number of 
individuals. Furthermore, as metformin can treat gestational diabetes, this may alter the foetal 
environment and thus affect the health of offspring. This review explores the epigenetic effects of 
metformin, including how they may modulate its glucose lowering and off-target activity, including 
potential protection from cardiovascular disease, cancer, cognitive decline and aging. 
 
Epigenetic modifications 
Epigenetic modifications fall under two main categories: histone modifications and DNA methylation. 
Although they do not directly interact with DNA, microRNAs are also often included as having 
epigenetic-like effects as they alter protein expression through the suppression of mRNA translation. 
 
Histone modifications 
DNA is wrapped around histone cores composed of two each of histone proteins H2A, H2B, H3 and 
H4; this structure is termed a nucleosome and comprises the fundamental unit of chromatin. DNA can 
be loosely packed and amenable to transcription as in euchromatin, or highly condensed and silenced 
as in heterochromatin; the state of organisation being determined by post-translational modifications 
to histone amino-terminal tails, most notably acetylation, phosphorylation and methylation. 
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Acetylation of histone lysine residues, particularly of H3 and H4, neutralises their positive charge and 
subsequently promotes an open chromatin structure.8 Histone hyperacetylation is thus considered a 
signature of active transcription. Histone acetylation is highly dynamic and regulated by two opposing 
families of enzymes, histone acetyltransferases (HATs) and histone deacetylases (HDACs). HATs add 
acetyl groups to lysine residues using acetyl-CoA as a cofactor. Of the two classes of HATs, Type-A 
HATs, including the CBP/p300 family, modify multiple sites in histone tails and act as transcriptional 
co-activators, whereas Type-B HATs, including HAT1, are cytoplasmic and acetylate newly formed 
histone proteins but not those already complexed to DNA.8 HDACs are divided into 4 classes; class I 
HDACs, including HDAC 1, 2, 3 and 8, are nucleic whereas class II HDACs, including HDAC 4, 5, 
6, 7, 9 and 10, move between the nucleus and cytoplasm.9 Class III HDACs, also known as sirtuins, 
include SIRTs 1 to 7 and are associated with longevity and decreased disorders of aging, including 
T2D.10 HDAC11 is the only class IV HDAC, of which little is known. Unlike class I, II and IV 
HDACs, which are zinc dependent, sirtuins rely on NAD+ for their deacetylating activity.  
Similar to acetylation, histone phosphorylation neutralises the positive charge of the histone.8 Serine, 
threonine and tyrosine residues serve as the phosphorylation/dephosphorylation sites for protein 
kinases and phosphatases respectively, in a process considered important for transcription, and 
therefore gene expression, as well as DNA repair, mitosis and apoptosis.11 
Unlike acetylation and phosphorylation, methylation of histone lysine or arginine residues does not 
alter the charge of the histone and can have varying influences on transcription depending on the 
specific residue methylated (denoted by the histone protein and the lysine [K] or arginine [R] that is 
methylated) and the degree of methylation (mono-, di- or trimethylation). Histone methylation 
involves the transfer of methyl groups from S-adenosylmethionine (SAM) to histone residues, 
catalysed by histone methyltransferases (HMT). Methylation of histone lysines H3K4, H3K36, and 
H3K79 is generally associated with active transcription, whereas methylation of H3K9, H3K27, and 
H4K20 is more commonly found on transcriptionally silent genes.12 Most HMTs are specific to a 
certain histone residue, for example enhancer of zeste homolog 2 (EZH2) trimethylates H3K27. 
Histone methylation is not as dynamic as acetylation and was thought to be a stable event until 
discovery of the first histone demethylase was reported in 2004.13 
Numerous other post-translational modifications to histones have been discovered, including 
ubiquitination, sumoylation, O-GlcNAcylation, and ADP-ribosylation, although it is less clear how 
these modifications impact gene expression and other processes affected by chromatin configuration.  
 
DNA methylation 
DNA methylation occurs when a methyl group is transferred from SAM to nucleotides by DNA 
methyltransferases (DNMTs). In vertebrates, it is thought that methylation only occurs to cytosine 
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bases in CpG dinucleotides.14 CpG dinucleotides are rare throughout the genome, accounting for only 
1% of cytosines, but occur at a high frequency in the majority (approximately 70%) of gene 
promoters.15 These regions of CpG clusters are termed CpG islands. Most cytosines in CpG islands 
are unmethylated, with hypermethylation of CpG islands generally resulting in transcriptional 
silencing due to decreased transcription factor binding and increased binding of methyl-CpG binding 
proteins,  which may initiate histone modification and subsequent chromatin condensation.14 
Four DNMTs with DNA methyltransfase activity have been identified, DNMT1, DNMT3a, DNMT3b 
and DNMT3c, while DNMT3L lacks methyltransferase activity and instead acts as a cofactor to de 
novo methyltransferases and DNMT2 methylates tRNA.16 DNMT3a and DNMT3b are the de novo 
methyltransferases; they establish methylation in previously unmethylated cytosines, whereas 
DNMT1 maintains a state of methylation, for example in daughter cells following replication.17 The 
recently described DNMT3c has been reported to silence retrotransposons in the germ cells of male 
mice.18 
 
MicroRNAs 
MiRNAs are short, non-coding RNAs that regulate gene expression through interaction with mRNA 
as part of the miRNA-induced silencing complex (miRISC). Due to their small size (approximately 
21-24 nucleotides) and ability to bind even when complementarity is not perfect, each miRNA can 
target hundreds of mRNAs. Subsequently, translation is repressed by the blocking of translation 
initiation factors and the degradation of target mRNAs through the recruitment of deadenylating and 
decapping enzymes, followed by nucleases.19  
 
Metformin 
Metformin reduces hyperglycaemia by decreasing hepatic gluconeogenesis and increasing insulin 
sensitivity.20 It is also used in the treatment of polycystic ovary syndrome (PCOS) to induce ovulation 
and regulate menstruation,21 and may have additional benefits with meta-analyses reporting a reduced 
risk of cardiovascular mortality22 and cancer23 in individuals on metformin therapy. Metformin may 
also be neuroprotective, with placebo-controlled randomized clinical trials reporting metformin 
improves cognitive function in the cognitively impaired, such as those with Alzheimer’s disease.24,25 
Metformin was also suggested as an antiaging drug as early as the 1970s,26 and is currently being 
investigated in randomised controlled trials such as the Targeting Aging with Metformin (TAME) 
trial.27 Metformin is generally well tolerated with gastrointestinal disturbances, particularly diarrhoea, 
being the most common side effect; less frequently liver damage and lactic acidosis have also been 
reported.28 While the exact mechanisms of action are not completely understood, metformin’s ability 
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to promote the phosphorylation and hence the activation of AMP activated protein kinase (AMPK) is 
considered to be central to its mode of action and to result in the inhibition of gluconeogenic genes.20 
Activation of AMPK, considered a major regulator of cellular metabolism, also impacts numerous 
pathways, not only those involved in glucose metabolism but also lipid metabolism, mitochondrial 
biogenesis, autophagy, cell growth and circadian rhythm.29  
 
There is emerging evidence that metformin-induced modulation of AMPK activity influences 
epigenetic processes. Given metformin’s widespread use, including in gestational diabetes and PCOS, 
this may be of concern. Studies exploring the effect of maternal metformin on offspring have been 
limited to short-term studies, and therefore the outcome regarding long-term metabolic effects is not 
yet known. Follow-up of the Metformin in Gestational diabetes (MiG) trial found offspring exposed 
prenatally to metformin had a preferable pattern of fat distribution at 2 years,30 while a Finnish study 
found children exposed to metformin and supplemental insulin in utero were heavier at 18 months 
than children exposed to insulin alone.31 Similarly, a trial of metformin use for PCOS during 
pregnancy found infants whose mothers took metformin were heavier at one year.32 Animal studies 
report mixed results; with one study by Salomaki et al.33 reporting increased weight gain and impaired 
glucose tolerance in mice on a high fat diet (HFD) exposed to metformin in utero, and a later study by 
the same group finding prenatal metformin exposure protected mice from HFD-induced weight gain 
and impaired glucose tolerance.34 
 
Metformin and epigenetic aging 
While the clinical effects of metformin as a pharmacological intervention to promote healthy aging 
and longevity are currently being investigated in clinical trials,27,35 few studies have attempted to do 
so in the context of epigenetics. Epigenetic markers of aging accumulate with hyperglycaemia, 
hyperinsulinaemia and metabolic syndrome,36,37 and correction of these metabolic abnormalities with 
metformin may ameliorate epigenetic aging. Metformin may also influence epigenetic aging through 
interaction with epigenetic modifying enzymes such as SIRT1, the HDAC associated with longevity. 
The clinical effects of metformin are similar to those of calorie restriction, an intervention known to 
prolong life,37 and there is a growing body of evidence that SIRT1 plays an important role in 
mediating the anti-aging effects of calorie restriction, including antidiabetic actions.10 In a randomised 
controlled trial, two months of metformin altered levels of several effectors associated with longevity, 
including increased SIRT1 expression in peripheral blood mononuclear cells.35 
In a recent observational study by Quach, et al.36, the degree of DNA methylation in peripheral blood 
(the ‘epigenetic clock’) was used to assess the effect of a variety of lifestyle factors on the rate of 
epigenetic aging, known as epigenetic age acceleration. Metformin did not significantly alter extrinsic 
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or intrinsic epigenetic age acceleration, although several other dietary and behavioural factors did. 
However, while epigenetic age acceleration has been found to correlate closely with expected 
longevity, it has not been validated as a means of assessing specific pharmacological effects, but 
rather is considered to reflect the ‘cumulative effect of an epigenetic maintenance system.’38 
Furthermore, as pointed out by the authors, lack of power and the observational design of this study 
may mask a real effect, and randomised controlled trials may provide a more convincing result.  
 
Metformin and histone modifications 
Metformin-induced activation of AMPK has been reported to impact histone modifications via 
multiple mechanisms, including modifications that both increase and decrease gene expression 
(Figure 1). This includes phosphorylation of HATs, increased SIRT1 activity, inhibition of class II 
HDACs, and potentially phosphorylation of histone residues. There is also evidence that metformin 
may influence HAT expression through AMPK-independent mechanisms, and inhibit HMT 
expression and histone ubiquitination. 
  
HATs 
The effect of AMPK activation on HATs varies, increasing the activity of some HATs and decreasing 
others, and thus metformin may likewise have varying effects. For example, Marin, et al.39 reported, 
using a mouse embryonic fibroblast model, that via AMPK activation, metformin induced HAT1 
phosphorylation, increasing its activity. Conversely, in multiple other studies, the phosphorylation of 
the HATs p300 and CREB-binding protein (CBP) by AMPK reduced their activity.40-43  
P300 and CBP are important transcriptional co-activators of multiple genes involved in inflammation 
and gluconeogenesis. He, et al.40 demonstrated that metformin induced phosphorylation of CBP at 
Ser436. This prevented the formation of the CREB-CBP-TORC2 transcription complex and decreased 
CBP occupancy at the promoter regions of gluconeogenic genes including peroxisome proliferator-
activated receptor gamma coactivator 1-alpha (PGC1α) and phosphoenolpyruvate carboxykinase 1 
(Pck1). Metformin significantly decreased blood glucose levels in wild-type mice but did not in mice 
with mutant CBP (S436A), suggesting this mechanism may play a key role in the antidiabetic activity 
of metformin. 
Similarly, metformin-induced AMPK activation results in p300 phosphorylation at Ser89, decreasing 
its enzymatic activity.42 AMPK-mediated p300 phosphorylation was found to reduce its interaction 
with nuclear receptors including PPARγ,43 and consequently may reduce the transcription of PPARγ 
target genes, including genes involved in lipid and glucose metabolism. As PPARγ is considered 
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beneficial in T2D, with PPARγ agonists such as thiazolidinediones prescribed as insulin-sensitising 
agents, it is unclear how this influences the effects of metformin on glucose metabolism. 
AMPK may also promote the proteasomal degradation of p300; Lim, et al.41 demonstrated that 
metformin and AICAR, an unrelated AMPK agonist, reduced p300 protein, but not mRNA, levels in 
hepatic stellate cells, with proteasome inhibition restoring protein levels. 
Metformin also increased mRNA and protein levels of Gcn5, a type A HAT, in diabetic mice and in a 
hepatocyte cell line.44 However, this was not influenced by an AMPK inhibitor, suggesting metformin 
alters Gcn5 expression through an unknown, AMPK-independent mechanism. 
 
HDACs 
As with HATs, the effect of metformin-induced AMPK activation has differing effects on the activity 
of different HDAC classes, decreasing the deacetylation of class II HDACs while increasing the 
activity of the class III HDAC SIRT1. Khan et al.45 demonstrated both an inhibitory effect on HDAC 
activity in rat liver and a consequent increase in global H3 acetylation following metformin treatment. 
HDAC inhibition with metformin has also been demonstrated in cancer cells.46 This may be a result of 
HDAC phosphorylation; it has been demonstrated that AMPK phosphorylates HDAC4, 5 and 7 at 
Ser259 and Ser498,47 and that such phosphorylation of HDAC5 results in its export from the nucleus 
and subsequently de-repression of target genes.48 This may contribute to the antidiabetic activity of 
metformin; a previous study reported that AMPK activation decreased HDAC5 association with the 
glucose transporter type 4 (GLUT4) gene, resulting in increased GLUT4 expression in human primary 
myotubes, suggesting a direct mechanism by which metformin could ameliorate insulin resistance in 
muscle cells.49 
As opposed to the inhibitory effect on class II HDACs, AMPK activation increases SIRT1 activity.44 
This is thought to be a result of NAD+ generation, as both metformin and overexpression of a 
constitutively active AMPK were reported to increase the NAD+/NADH ratio in myotubes.50 
Metformin may also increase SIRT1 gene expression; in a randomised controlled trial, two months of 
metformin treatment increased SIRT1 mRNA and protein levels in peripheral blood mononuclear 
cells, although no increase in SIRT1 deacetylase activity was detected.35 Effects may differ in cancer 
cells, where metformin has been shown to reduce SIRT1 protein expression.51 This is mediated 
through effects on miR-34a, as discussed in a later section.  
In animal models, increased SIRT1 activity with metformin has been associated with inhibition of 
gluconeogenesis in the liver, implicating SIRT1 with the antidiabetic actions of metformin. Caton, et 
al.44 found metformin treatment increased the NAD+/NADH ratio and SIRT1 activity in diabetic mice 
while decreasing plasma insulin and glucose as well as expression of the gluconeogenic enzyme Pck1. 
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Co-incubation of hepatocytes with inhibitors of either AMPK or SIRT1 reduced the antidiabetic 
effects of metformin, specifically increasing cellular glucose levels and Pck1 expression and activity. 
There is also evidence that metformin may reduce cellular aging and improve cardiovascular health 
through SIRT1, in particular by protecting vascular endothelial cells from cellular stress. In human 
umbilical vascular endothelial cells, treatment with metformin increased SIRT1 expression and 
activity and reduced signs of cellular aging and production of reactive oxygen species.52 These effects 
were prevented when AMPK was silenced by siRNA. Similarly, Arunachalam, et al.53 found 
metformin increased SIRT1 expression and conferred protective effects in cultured mouse 
microvascular endothelial cells exposed to high glucose, including increased levels of the anti-
apoptotic Bcl-2 protein and reduced cellular senescence. Silencing SIRT1 prevented these protective 
effects. 
SIRT1 has also been associated with neuroprotection in cell-based and animal models of aging and 
T2D and controlled clinical trials with resveratrol, a SIRT1 activator, have shown improved cognitive 
function.54 In mice on a high fat diet, metformin increased hippocampal SIRT1 gene expression.55 
Although this study did not find significant changes in memory or learning with metformin treatment, 
this mechanism could potentially contribute to the reported neuroprotective effects of metformin. 
Histone methylation 
There is evidence that metformin can influence the methylation of numerous histone lysine residues. 
While both increases and decreases of lysine methylation have been reported, all these modifications 
are consistent with an increase in gene expression due to the previously mentioned fact that 
methylation of lysine residues can either activate (H3K4, H3K36) or repress (H3K9, H3K27) 
transcription. In particular, as these studies were conducted using cancer cells to investigate the 
potential anticancer activity of metformin, changes in histone methylation due to metformin treatment 
may lead to increased expression of tumour suppressor genes. For example, Banerjee, et al.46 reported 
that metformin treatment decreased H3K9 and H3K27 methylation, as well as increased H3K4 
methylation in breast cancer cells, both globally and specifically at the promoter of the tumour 
suppressor gene E-cadherin. These modifications may be a result of inhibition of HMTs; reductions 
of mRNA and protein expression of SUV39H156 and MMSET,57 HMTs that influence the methylation 
of H3K9 and H3K27 respectively, have been reported in metformin treated prostate cancer cells. The 
mechanism by which metformin may inhibit HMTs is unknown as these studies did not examine 
whether AMPK is directly responsible for the reported effects. 
Conversely, one study has reported that AMPK can increase histone demethylase activity, although 
this study did not use metformin treatment. Tanaka, et al.58 demonstrated that AMPK can reduce 
H3K36 methylation through lysine-specific demethylase 2A (KDM2A) activity. AMPK activation by 
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AICAR reduced H3K36 dimethylation at the rDNA promoter with subsequent reduced transcription 
of rDNA in breast cancer cells. KDM2A knockdown prevented these effects. 
 
Other histone modifications 
The direct influence of metformin on histone phosphorylation has not been studied, however Bungard, 
et al.59 found that AMPK activation by a related biguanide, phenformin, resulted in the 
phosphorylation of H2B at Ser36 in mouse embryonic fibroblasts. Abrogation of phosphorylation by 
Ser36>Ala36 substitution reduced the transcription of AMPK target genes. Furthermore, a study of 
Sertoli cells found AMPK knockout resulted in a reduction of phosphorylated H2B.60 
AMPK activation has also been associated with a decrease in ubiquitination and O-GlcNAcylation of 
residues on H2B. Xu, et al.61 reported that activation of AMPK by AICAR in mouse embryonic 
fibroblasts resulted in the phosphorylation of O-linked β-N-acetylglucosamine (O-GlcNAc) 
transferase, the enzyme responsible for histone O-GlcNAcylation, i.e. the addition of O-linked N-
acetylglucosamine (O-GlcNAc). This decreased the affinity of the enzyme for chromatin and thus 
reduced O-GlcNAcylation of H2B at Ser112, both globally and at the region of several target genes 
associated with repression of these genes. As O-GlcNAcylation is thought to promote histone 
ubiquitination, they also found reduced ubiquitination at H2BK120. Although this study used a 
different AMPK activator, metformin has been proven to decrease H2BK120 ubiquitination in breast 
cancer cells.62 These studies both associated ubiquitination and O-GlcNAcylation with increased gene 
expression, although both modifications have also been associated with gene silencing and linked to a 
variety of other histone modifications that may alter chromatin structure.61,63 
 
Metformin and DNA methylation 
Reported effects of metformin on DNA methylation include both hypo and hypermethylation at the 
promoters of different genes.46,64-66 Furthermore, it has been reported that AMPK directly inhibits 
DNA methyltransferase activity, while metformin may indirectly reduce the activity of endogenous 
DNMT inhibitors. As a result, the overall effect of metformin on DNA methylation and subsequent 
gene expression is unclear. 
Reduced DNA methylation with metformin treatment has been reported at the insulin gene promoter 
in a β cell line cultured using high glucose concentrations65 and at the promoter of the tumour 
suppressor gene E-cadherin in both cancer cell lines and in white blood cells from diabetics,46 leading 
to increased expression of the respective genes. These results thus implicate DNA demethylation in 
the antidiabetic and potential anti-cancer actions of metformin. Additionally, reduced methylation of 
transporter genes SLC22A1, SLC22A3, and SLC47A1, all involved in hepatic transport of metformin, 
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was reported in the livers of diabetics receiving metformin compared to those not receiving any 
antidiabetic medication.66 Interestingly, these changes were not apparent in patients receiving 
metformin plus insulin. These changes in methylation may be a result of reduced DNMT activity; 
activation of AMPK by metformin has been reported to phosphorylate DNMT1 at Ser730 and 
consequently inhibit its methyltransferase activity.39 This was associated with a decrease in promoter 
methylation of six target genes in wild type mouse embryonic fibroblasts, but not in AMPK knockout 
cells or cells with DNMT1 Ser730>Ala730 substitution. Furthermore, metformin treatment reduced 
DNMT1 protein expression in several human lung cancer cell lines.67 
Conversely, several studies indicate that metformin may induce DNA hypermethylation via increased 
activity of S-adenosylhomocysteine hydrolase (SAHH). SAHH hydrolyses and thus inactivates 
S-adenosylhomocysteine (SAH), a feedback inhibitor of DNMT activity. Recently, it was reported 
that metformin decreased SAH levels in non-malignant breast epithelial cells and increased global 
DNA methylation in a variety of malignant and non-malignant cells.68 AMPK knockout cells were 
resistant to these changes. Zhong, et al.64 demonstrated that metformin increases SAHH activity and 
alters the methylation of numerous gene promoters in endometrial cancer cells. A SAHH inhibitor 
blocked the metformin-induced hypermethylation of five genes. Interestingly, the metformin-induced 
increase in SAHH activity may itself be due to DNA hypermethylation. The long noncoding RNA 
H19 has been demonstrated to bind and thus inhibit SAHH,64 and Yan, et al.69 reported increased 
methylation of the H19 promoter and subsequent reduced H19 expression with metformin treatment 
in endometrial and ovarian cancer cells. 
 
Metformin and microRNAs 
Metformin has been reported to alter the expression of numerous miRNAs. Alterations in miRNA 
expression by metformin may be partially explained by an increase in DICER, one of the key 
enzymes in miRNA processing. Increases in DICER protein levels have been reported in metformin 
treated diabetic humans and mice,70 and in cancer cells.71 This increase was also reported in cells 
treated with AICAR, suggesting AMPK activation as a mechanism.71 
 
Metformin-altered miRNAs in cancer 
The potential anti-cancer properties of metformin have been linked to the regulation of numerous 
miRNAs (see Table 1). MiRNAs that may be important in the potential anti-cancer activity of 
metformin include upregulation of the let-7 family, miR-26a and miR-34a and downregulation of 
miR-181a, miR-221 and miR-222. Let-7 miRNAs are downregulated in many cancers and target 
mRNA of oncogenes including Ras and c-Myc,72 while also inhibiting expression of the SAHH 
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inhibitor H19 and thus impacting DNA methylation (see previous section).64 MiR-26a is also 
downregulated in many tumours and has been found to inhibit proliferation and induce apoptosis 
through the suppression of a number of oncogenes including EZH2, Oct4 and Notch-1.73 MiR-34a is a 
transcriptional target of the tumour suppressor p53 and inhibits a number of oncogenes including c-
Myc, c-MET and Notch, in addition to the anti-apoptotic Bcl-2 and the HDAC SIRT1.74 The 
oncogenic miR-181a induces and maintains stem cell phenotypes in cancer cells by targeting 
transcription factors involved in cell differentiation,75 while miR-221 and miR-222 promote cancer 
proliferation through the suppression of cell cycle inhibitors such as p27 and p57.76,77 
 
Metformin-altered miRNAs in diabetes and diabetes complications 
MiRNAs may contribute to the beneficial effects of metformin in diabetics, particularly in reducing 
the risk of diabetes-associated conditions such as cardiovascular disease, liver disease and diabetic 
nephropathy. 
In one study, Santovito, et al.78 reported 25 miRNAs with altered expression in diabetics, including 
downregulation of let-7 family miRNAs. Twelve months of metformin treatment combined with 
lifestyle changes significantly increased the expression of let-7a and let-7f. Although overexpression 
of let-7 has been associated with reduced insulin secretion and insulin sensitivity in mice,79 a recent 
study by Brennan, et al.80 suggests let-7 miRNAs may protect against inflammation in diabetic 
atherosclerotic plaques. Additionally, the internal mammary arteries of diabetics on metformin were 
found to have lower levels of miR-221 and miR-222 compared to diabetics not on metformin.81 
Inhibition and transfection of these miRNAs respectively reduced and increased the proliferation of 
isolated vascular smooth muscle cells, leading the authors to suggest that this mechanism may protect 
against intimal thickening in diabetes. Metformin may also improve impaired angiogenesis in diabetic 
vascular disease through miR-34a-mediated regulation of SIRT1 expression. Arunachalam, et al.82 
found metformin treatment lowered miR-34a expression, increased SIRT1 expression, increased 
expression of vascular growth factor Ang1 and subsequently increased tube formation in mouse 
microvascular endothelial cells. This downregulation of miR-34a is contradictory to the results found 
by multiple experiments in cancer cells and indicates metformin may have differing effects on 
miRNA expression in cancer cells compared to non-malignant cells. 
 Downregulation of miR-34a has also been found in livers of metformin treated mice. In a mouse 
model of liver disease, metformin protected mice from liver fibrosis, inflammation and steatosis and 
resulted in the downregulation of miR-34a, as well as miR-376a, miR-127, miR-300 and miR-342-3p, 
and the upregulation of miR-122, miR-194, miR-101b, and miR-705.83 MiR-122 is the prominent 
miRNA in the liver and mice lacking the miR-122 gene develop liver disease and hepatocellular 
carcinoma,84 while increased expression of miR-127 was found to inhibit the proliferation of rat 
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hepatocytes and thus may impede regeneration following injury.85 Meng, et al.86 found metformin 
treatment decreased levels of miR-291b-3p in the livers of mice on a high fat diet, with levels of this 
miRNA correlating with lipid accumulation. Overexpression of miR-291b-3p increased hepatic lipid 
accumulation in mice fed a normal diet, as well as AST and ALT levels, common biomarkers of liver 
damage. Interestingly, miR-291b-3p was shown to target AMPKα1, the catalytic subunit of AMPK, 
leading the authors to suggest that miR-291b-3p suppression contributes to the increase of AMPK 
activity by metformin, and thus may mediate numerous downstream effects. 
Low expression of miR-192 has been associated with the progression of diabetic nephropathy and in 
one study circulating miR-192 levels inversely correlated with markers of impaired renal function 
(plasma urea and creatinine) in healthy subjects.87 In this study, three months of metformin treatment 
increased plasma miR-192 concentration in diabetics by nearly 50%, although it did not investigate if 
this resulted in a mitigation of nephropathy. 
Limitations of studies 
The majority of studies reporting epigenetic effects of metformin have been conducted using mouse 
models or cell culture, with a few exceptions using human metformin users (increased SIRT1 
expression,35 DNA hypomethylation of certain genes46,66 and changes in miRNA expression).78,87 
There are major limitations to these approaches due to differences in physiology between mice and 
humans and between transformed cell lines in vitro and human tissue in vivo. Furthermore, many 
studies used suprapharmacological concentrations of metformin in the millimolar concentration range, 
well above the 40-70 µM and 1-40 µM plasma concentrations reported in the portal vein and systemic 
circulation respectively following therapeutic doses.88 
This may account for some of the disparate results of the studies. For example, studies reporting DNA 
hypomethylation with metformin were conducted on diabetics taking therapeutic doses of 
metformin,46,66 or used micromolar doses of 500 µM65 or 20 µM.67 Conversely, studies associating 
metformin with DNA hypermethylation used suprapharmacological concentrations between 1 and 10 
mM.64,68-69 For a summary of the published studies, including the metformin dose and the model used, 
see Supplementary Table 1. 
Additionally, the reported studies have largely investigated epigenetics in the context of potential 
beneficial effects of metformin, namely diabetes, cancer, atherosclerosis, cognitive function and 
aging, and have not investigated if these epigenetic modifications could have detrimental side effects. 
Finally, it is yet to be reported if metformin use during pregnancy, in conditions such as gestational 
diabetes or PCOS, may imprint epigenetic signatures onto the offspring that may program long-term 
metabolic changes. 
Conclusion 
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Epigenetics is a rapidly growing field that has been linked with numerous disorders, including T2D. 
The widely used antidiabetic drug metformin can reportedly modulate numerous epigenetic processes 
that may contribute to its primary hypoglycaemic action, but may also result in off-target effects, both 
beneficial and potentially deleterious. Metformin can alter the activity of many different epigenetic 
modifying enzymes, primarily through the phosphorylating actions of AMPK. However, these include 
modifications that act to both increase and decrease gene expression. Furthermore, the literature 
suggests that metformin has opposing effects within the major groups of epigenetic modifying 
enzymes. Generally, it decreases the activity of most classes of HATs, HDACs and DNMTs through 
AMPK-mediated phosphorylation, and at the same time reportedly increases HAT1 and SIRT1 
activity, and decreases the influence of DNMT inhibitors. This, together with the previously 
mentioned limitations of published studies, means it is difficult to make generalisations regarding the 
effects of metformin on the epigenome, subsequent gene expression and what impact this may have 
on the health of the millions of metformin users worldwide. 
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Table 1: Effect of metformin on miRNAs in cancer cells 
Cell/tissue source Metformin 
dose 
miRNAs altered Observed effects Reference 
Breast cancer cell lines 
MCF-7, BT-474 and 
SUM-159 
500 µM MiR-33a 
upregulated 
MiR-33a downregulated c-Myc and 
IRS-2 
Blandino, et 
al.71 
 
Breast cancer cell line 
MDA-MB-231 
10 mM MiR-26a 
upregulated
MiR-26a downregulated PTEN, 
decreased viability
Cabello, et 
al.89 
Breast cancer cell line 
MCF-7 
1 mM Let-7a, miR-32, 
miR-96 
upregulated 
MiR-183 
downregulated 
Metformin inhibited formation of 
mammospheres 
Oliveras 
Ferraros, et 
al.75 
Breast cancer cell line 
MCF-7 
From 1 mM MiR-34a 
upregulated 
MiR-34a downregulated SIRT1 
Metformin increased susceptibility 
to oxidative stress 
Do, et al.51 
Breast cancer cells 
lines MCF7, MDA-
MB, BT-549, HCC70 
10 mM MiR-193a and 
miR-193b 
upregulated 
MiR-193b downregulated fatty acid 
synthase (FASN) protein and 
induced apoptosis in BT-549 cancer 
cells but not non-cancerous 
MCF10A cells 
Wahdan-
Alaswad, et 
al.90 
Breast cancer cell line 
MCF7, endometrial 
cancer cell line ARK2 
2 mM Let-7 upregulated Let-7 and AICAR downregulated 
H19 
Zhong, et al.64 
Cholangiocarcinoma 
cell lines HCCC-9810, 
RBE, SSP25 and 
Hucct1 
20-40 mM MiR-124, miR-
182, miR-27b and 
let-7b upregulated 
MiR-221 and miR-
181a 
downregulated 
MiR-124 downregulated CDK2, 
CDK4, CyclinD1 and CyclinE1 
MiR-182 and miR-27b 
downregulated CDK2 and CyclinD1 
Let-7b downregulated CyclinD1 
MiR-124, miR-182, miR-27b and 
let-7b decreased proliferation 
Mir-221 and miR-181a upregulated 
p27 and increased proliferation 
Jiang, et al.91 
Hepatocellular 
carcinoma cell line 
Huh7 
10 mM 33 upregulated 
including let-7a, 
let-7b, let-7e, miR-
34a, miR-26a, 
miR-181a. 
18 downregulated 
Metformin decreased proliferation, 
downregulated angiogenin, cyclin 
D1, Cdk4 and cyclin E,  
Miyoshi, et 
al.72 
Hepatocellular 
carcinoma cell line 
HepG2 
2.5 µM MiR-23a 
upregulated 
MiR-23a downregulated FOXA1, 
induced apoptosis 
Sun, et al.92 
Gastric cancer cell line 
MKN74 
10 mM 30 miRNAs 
upregulated, 
including let-7 
family. 
21 downregulated 
Metformin decreased proliferation, 
downregulated cyclinD1 
Kato, et al.93 
Lung cancer cell lines 
A549 and NCI-H358 
10 mM MiR-222 
downregulated 
Metformin upregulated p27, p57 and 
PTEN and decreased proliferation 
Wang, et al.76 
Pancreatic cancer cell 
lines AsPC-1, AsPC-
1-GTR, MiaPaCa-2, 
and MiaPaCa-2-GTR 
20 mM Let-7a, let-7b, 
miR-26a, miR-101, 
miR-200b, and 
miR-200c 
upregulated 
MiR-26a downregulated EZH2, 
Oct4, Notch-1, and EpCAM 
MiR-26a and let-7b decreased 
growth of pancreatospheres 
Bao, et al.73 
Pancreatic cancer cell 
line Panc02  
0.5 mM MiR-34a 
upregulated 
MiR-34a downregulated Notch. 
Metformin decreased tumour sphere 
formation 
Cifarelli, et 
al.94 
Pancreatic cancer cell 
lines Panc1 and 
Sw1990  
5 mM MiR-26a, miR-192, 
and let-7c 
upregulated 
MiR-26a downregulated HMGA1, 
reduced cell proliferation and 
migration, and induced apoptosis 
Li, et al.95 
Pancreatic cancer cell 
line Panc1 
10 mM 78 upregulated 
including let-7 
family and miR-
150 
51 downregulated 
Metformin downregulated cyclinD1 
and Cdk4 and decreased 
proliferation 
Kato, et al.96 
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including miR-7 
Pancreatic cancer cell 
line Panc1 
20 mM MiR-221 
downregulated
MiR-221 downregulated p27 and 
decreased G1-phase arrest
Tanaka, et al.77 
Prostate cancer cell 
line PC-3 
1-5 mM 10 upregulated 
12 downregulated 
including miR-
181a 
Metformin decreased proliferation Avci, et al.97 
Prostate cancer cell 
line Vcap 
5 mM MiR-30a, miR-143 
and miR-196b 
upregulated 
MiR-30a downregulated SOX4, 
decreased proliferation, migration 
and invasion of cancer cells 
Zhang, et al.98 
Renal cancer cell line 
786-O 
10 mM MiR-26 
upregulated 
MiR-26a downregulated Blc-2 and 
CyclinD1, decreased proliferation 
Yang, et al.99 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
Legends to figure 
Figure 1: Postulated mechanisms by which metformin may modify histones via AMPK 
activation.  
Metformin phosphorylates (P) and activates AMPK, which subsequently has been found to activate 
gene expression through the phosphorylation and inactivation of HDACs and activation of HAT1, 
leading to increased acetylation (Ac) of histone (H) tails. AMPK may also increase gene expression 
through phosphorylation of histone H2B. Conversely, AMPK may also suppress gene transcription 
via increasing cellular NAD+ levels and thus increasing SIRT1 deacetylation activity and via 
phosphorylation and inactivation of HATs p300 and CBP. 
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